Key Insights

Highlights

Success Rate

61% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 67/100

Termination Rate

23.3%

7 terminated out of 30 trials

Success Rate

61.1%

-25.4% vs benchmark

Late-Stage Pipeline

27%

8 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results61% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (8)
P 1 (5)
P 2 (3)
P 3 (7)
P 4 (1)

Trial Status

Completed11
Unknown10
Terminated7
Not Yet Recruiting1
Enrolling By Invitation1

Trial Success Rate

61.1%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT03626688Phase 3Completed

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT04222972Phase 3Terminated

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03683186Phase 3Enrolling By Invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03037385Phase 1Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT04862780Phase 1Terminated

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

NCT05241873Phase 1Terminated

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT03331991CompletedPrimary

Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel

NCT04476979Phase 2Completed

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

NCT05330507Unknown

Prospective, Observational Study of Wellinks Effect on COPD Hospital Readmissions

NCT04084678Phase 3Terminated

A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

NCT05134402Completed

Recording of Multiple Nights Using a New Contactless Device (Sleepiz One Connect) in Obstructive Sleep Apnea

NCT03321968Phase 3Completed

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

NCT03085069Phase 2Unknown

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

NCT04234152Not ApplicableCompleted

Complete Shielding of Multivitamins to Reduce Toxic Peroxides in the Parenteral Nutrition: A Pilot Study

NCT05345080Not ApplicableUnknown

Houston "Breathe Easy" Healthy Homes-Based Model for Multifamily Rental Communities

NCT04365101Phase 1Unknown

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT05286918Not ApplicableNot Yet Recruiting

Antibiotic Stewardship in AECOPD Through CRP-Guided Management

NCT05126654Not ApplicableUnknown

Partially Hydrolyzed Guar Gum (PHGG) for Amelioration of Chronic Obstructive Pulmonary Disease (COPD)

NCT04729478Not ApplicableUnknown

Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea

NCT03571542Not ApplicableUnknownPrimary

Evaluation of the Respiratory Function in Renal Transplanted Children

Scroll to load more

Research Network

Activity Timeline